According to a study published by Insure Insights, the global CAR T-cell therapy market is estimated to grow at a CAGR of 33.1% during the forecast period. CAR T-cell therapy is a type of treatment in which a patient’s T cells are changed in the laboratory to bind to cancer cells and kill them. In the process, blood from a vein in the patient’s arm flows through a tube to a machine (not shown), which segregates the white blood cells, including the T cells, and sends the rest of the blood back the patient’s body. Further, the gene for a particular receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells can bind to an antigen on the cancer cells and kill them.

Top Driver: The Rising Prevalence of Cancer and the Increasing Number of Patients

The rising prevalence of cancer and the increasing number of patients showing response failure to alternative treatments is expected to propel the growth of the global CAR-T cell therapy market. A growing number of adults and children suffering from cancer is expected to stimulate the demand for an effective and reliable therapeutic treatment to improve the quality of patient’s lives. In addition to this, the development of novel and effective therapy options to treat symptoms of the disease is also an essential factor contributing to the growth of the CAR-T cell therapy market. Further, increasing government expenditure in research for cell therapy in cancer and several initiatives for improving health care infrastructure leads to the growth of the market.

On the other hand, side effects of cell therapy may lead to cytokine release syndrome (CRS) and other neurological problems that include delirium, seizures, coma, and hallucinations. This factor is expected to hamper the market growth.

Research based Segment Accounts for the Largest Market Share

The global CAR T-cell therapy market has been segmented into research and commercialized based on the modality. The research-based market is expected as the vital source of revenue in the CAR-T cell therapy market as most of the products are under the clinical investigation stage. A considerable number of research centers, such as the City of Hope, are at the frontline of CAR T-cell Therapy. Hence, a profitable method of cancer management in the coming years. Based on the therapy, the market is segmented into T cell receptor, CAR t- cell therapy, and tumor infiltration lymphocytes. Based on the Indication outlook, the market is segmented into solid tumors and hematological malignancies.

    Larger Subject Sample Size and the Presence of a Substantial Number of Research Centers to Benefit North America Market

North America is the dominating region holding the largest market share during the forecast period. The growth is attributed to factors such as larger subject sample size, the presence of a substantial number of research centers, and a high number of sponsors from the U.S. for clinical trials. In addition to this, CAR T-cell therapeutics have secured regulatory approvals in countries such as the U.S and Canada.

Players to Focus on Mergers and Acquisitions

The major market players operating in the global CAR T-cell therapy are Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.

Autolus Therapeutics PLC: In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autologous enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL), by the US FDA.

Scope of the Report

By Modality

• Research
• Commercialized

By Therapy Type

• T-cell receptor
• CAR T-cell therapy
• Tumor infiltration lymphocytes

By Indication

• Solid tumor
• Hematologic malignancies

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.